Multiformat T-Cell-Engaging Bispecific Antibodies Targeting Human Breast Cancers

Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies

(2014) Shannon L. Maude et al.   CANCER JOURNAL

Antitumor Efficacy of a Bispecific Antibody That Targets HER2 and Activates T Cells

(2014) T. T. Junttila et al.   CANCER RESEARCH

In Vitro and In Vivo Evaluation of Cysteine and Site Specific Conjugated Herceptin Antibody-Drug Conjugates

(2014) Dowdy Jackson et al.   PLoS One

A general approach to site-specific antibody drug conjugates

(2014) Feng Tian et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Trastuzumab Emtansine: A Novel Antibody-Drug Conjugate for HER2-Positive Breast Cancer

(2013) I. Krop et al.   CLINICAL CANCER RESEARCH

Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies

(2013) Y Cao et al.   ONCOGENE

Synthesis of Heterobifunctional Protein Fusions Using Copper-Free Click Chemistry and the Aldehyde Tag

(2012) Jason E. Hudak et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Bispecific Antibodies and Trispecific Immunocytokines for Targeting the Immune System Against Cancer

(2012) Philippe Fournier et al.   BIODRUGS

Pertuzumab

(2012) Gillian M. Keating   DRUGS

Synthesis of Bispecific Antibodies using Genetically Encoded Unnatural Amino Acids

(2012) Chan Hyuk Kim et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Synthesis of site-specific antibody-drug conjugates using unnatural amino acids

(2012) J. Y. Axup et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines

(2011) D. M. Collins et al.   ANNALS OF ONCOLOGY

EpCAM/CD3-Bispecific T-cell Engaging Antibody MT110 Eliminates Primary Human Pancreatic Cancer Stem Cells

(2011) M. Cioffi et al.   CLINICAL CANCER RESEARCH

Site-Specific Coupling and Sterically Controlled Formation of Multimeric Antibody Fab Fragments with Unnatural Amino Acids

(2011) Benjamin M. Hutchins et al.   JOURNAL OF MOLECULAR BIOLOGY

Serum HER2 Level Measured by Dot Blot: A Valid and Inexpensive Assay for Monitoring Breast Cancer Progression

(2011) Li-Duan Tan et al.   PLoS One

Readily Accessible Bicyclononynes for Bioorthogonal Labeling and Three-Dimensional Imaging of Living Cells

(2010) Jan Dommerholt et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Bispecific Antibodies for Cancer Immunotherapy

(2010) Dafne Müller et al.   BIODRUGS

Evidence for a TCR Affinity Threshold Delimiting Maximal CD8 T Cell Function

(2010) D. A. Schmid et al.   JOURNAL OF IMMUNOLOGY

Bispecific antibodies for cancer therapy

(2010) Patrick Chames et al.   mAbs

T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells

(2010) Ralf Lutterbuese et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Antibody−Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies

(2009) Laurent Ducry et al.   BIOCONJUGATE CHEMISTRY

The Trifunctional Antibody Ertumaxomab Destroys Tumor Cells That Express Low Levels of Human Epidermal Growth Factor Receptor 2

(2009) M. Jager et al.   CANCER RESEARCH

Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate

(2008) G. D. Lewis Phillips et al.   CANCER RESEARCH

Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts

(2008) Kristin McLarty et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING